Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 264

1.

Translating the evidence on atypical depression into clinical practice.

Hyman Rapaport M.

J Clin Psychiatry. 2007;68 Suppl 3:31-6. Review.

2.

Transdermal selegiline: the new generation of monoamine oxidase inhibitors.

Patkar AA, Pae CU, Masand PS.

CNS Spectr. 2006 May;11(5):363-75. Review.

PMID:
16641841
3.

Translating the evidence on atypical depression into clinical practice.

Rapaport MH, Thase ME.

J Clin Psychiatry. 2007 Apr;68(4):e11. Review.

4.

Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.

Feiger AD, Rickels K, Rynn MA, Zimbroff DL, Robinson DS.

J Clin Psychiatry. 2006 Sep;67(9):1354-61.

PMID:
17017821
5.

The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability.

Robinson DS, Amsterdam JD.

J Affect Disord. 2008 Jan;105(1-3):15-23. Epub 2007 Jun 13. Review.

PMID:
17568687
7.

Selegiline transdermal system: current awareness and promise.

Pae CU, Lim HK, Han C, Neena A, Lee C, Patkar AA.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Aug 15;31(6):1153-63. Epub 2007 May 10. Review.

PMID:
17614182
8.

Selegiline transdermal system: a novel treatment option for major depressive disorder.

Nandagopal JJ, DelBello MP.

Expert Opin Pharmacother. 2009 Jul;10(10):1665-73. doi: 10.1517/14656560903048942. Review.

PMID:
19527191
9.

Moclobemide: therapeutic use and clinical studies.

Bonnet U.

CNS Drug Rev. 2003 Spring;9(1):97-140. Review.

10.

The transdermal delivery system of monoamine oxidase inhibitors.

VanDenBerg CM.

J Clin Psychiatry. 2012;73 Suppl 1:25-30. doi: 10.4088/JCP.11096su1c.04. Review.

11.

Monoamine oxidase inhibitors: a new generation.

Robinson DS.

Psychopharmacol Bull. 2002 Summer;36(3):124-38.

PMID:
12473970
13.

Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males.

Barrett JS, Hochadel TJ, Morales RJ, Rohatagi S, DeWitt KE, Watson SK, Darnow J, Azzaro AJ, DiSanto AR.

J Clin Pharmacol. 1997 Mar;37(3):238-47.

PMID:
9089426
14.

MAOIs and transdermal delivery.

Vandenberg CM.

J Clin Psychiatry. 2012 Sep;73(9):e28. doi: 10.4088/JCP.11096tx6c.

15.

Transdermal selegiline.

Patkar AA, Pae CU, Zarzar M.

Drugs Today (Barc). 2007 Jun;43(6):361-77. Review.

PMID:
17612708
16.

Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression.

Thomas SJ, Shin M, McInnis MG, Bostwick JR.

Pharmacotherapy. 2015 Apr;35(4):433-49. doi: 10.1002/phar.1576. Review.

17.

Transdermal selegiline: targeted effects on monoamine oxidases in the brain.

Wecker L, James S, Copeland N, Pacheco MA.

Biol Psychiatry. 2003 Nov 15;54(10):1099-104.

PMID:
14625153
18.

The role of monoamine oxidase inhibitors in depression treatment guidelines.

Thase ME.

J Clin Psychiatry. 2012;73 Suppl 1:10-6. doi: 10.4088/JCP.11096su1c.02.

19.
20.

Current prescription patterns and safety profile of irreversible monoamine oxidase inhibitors: a population-based cohort study of older adults.

Shulman KI, Fischer HD, Herrmann N, Huo CY, Anderson GM, Rochon PA.

J Clin Psychiatry. 2009 Dec;70(12):1681-6. doi: 10.4088/JCP.08m05041blu. Epub 2009 Oct 20.

PMID:
19852903

Supplemental Content

Support Center